Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
113.50    0.00 (0.00%)
Bid:
110.00
Ask:
117.00
Spread: 7.00 (6.364%)
Market Cap: £15.31m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Full Year Trading Update

13 Jan 2026 07:00

RNS Number : 5928O
Itaconix PLC
13 January 2026
 

For release: 07.00, 13 January 2026

Itaconix plc

("Itaconix" or the "Company")

Full Year Trading Update

Record revenues exceeding $10 million for the first time, driven by third consecutive record half year and strong customer momentum

Itaconix plc (AIM: ITX) (OTCQB: ITXXF), a leading innovator in high-performance plant-based specialty polymers, is pleased to provide a trading update for the year ended 31 December 2025.

Unaudited revenues for FY 2025 increased 59% year-on-year to $10.3 million (FY 2024: $6.5 million), exceeding $10 million for the first time. This performance was underpinned by a third consecutive record half year, with revenues of $5.5 million in H2 2025, up from $4.8 million in H2 2024.

Revenue growth was generated across both existing and new customers, spanning major applications and geographies. Demand for the Company's patented plant-based polymers continued to strengthen as global consumer product manufacturers increasingly adopt sustainable, high-performance ingredients to enhance formulation performance and deliver added value in detergent, hygiene and beauty products. This growth in revenue and a step change in the Company's commercial traction have enabled Itaconix to invest further in demand generation and support for 2026.

The Board remains optimistic about the Company's prospects for 2026 and believes that Itaconix is well positioned to deliver continued revenue growth, supported by a growing customer pipeline, expanding product adoption and a scalable, capital-efficient operating model. 

Further details on 2025 trading performance and the outlook for 2026 will be provided with the Company's FY 2025 results, expected in late March 2026.

John R. Shaw, CEO of Itaconix, commented:

"2025 was a milestone year for Itaconix. Delivering record revenues of over $10 million for the first time, alongside our third consecutive record half year, demonstrates the accelerating commercial momentum behind our technology and customer proposition.

"We are seeing growing validation from both new and existing customers as our plant-based specialty polymers become embedded in next-generation consumer products where performance, sustainability and value are all critical.

"Entering 2026, Itaconix is operating from a position of strength: we are well funded, capital efficient and supported by a deep and expanding revenue pipeline. With increasing scale, disciplined execution and strong customer engagement, we believe the Company is firmly on track towards building a large, profitable and enduring specialty ingredients business, delivering long-term value for shareholders."

- ends -

Enquiries:

Itaconix plc +1 603 775 4400

John R. Shaw / Laura Denner

Rosewood +44 (0) 207 653 8704

Financial PR

John West / Llewellyn Angus / Lily Pearce

Canaccord Genuity +44 (0) 7523 8000

Nominated Adviser and Broker

Adam James / Harry Pardoe

 

About Itaconix

Itaconix uses its proprietary plant-based polymer technology platform to produce and sell specialty ingredients that improve the safety, performance, and sustainability of consumer products. The Company's current ingredients are enabling and leading new generations of cost-effective, decarbonized consumer products in home and personal care.

www.itaconix.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBIGDBXBBDGLD
Date   Source Headline
19th May 20207:00 amRNSNew Loan Funding
5th May 20209:05 amRNSSecond Price Monitoring Extn
5th May 20209:00 amRNSPrice Monitoring Extension
5th May 20207:00 amRNSStrong Revenue Momentum and Extended Funding
17th Mar 20207:00 amRNSCompany Update on Funding and Business Plan
4th Mar 20207:00 amRNSNew Collaboration in Biodegradable Packaging
25th Feb 20207:00 amRNSOrder for Sustainable Detergent Ingredient
20th Feb 20207:00 amRNSHolding(s) in Company
20th Feb 20207:00 amRNSHolding(s) in Company
18th Feb 20202:49 pmRNSHolding(s) in Company
18th Feb 20209:31 amRNSBlock listing Interim Review
12th Feb 20207:15 amRNSNew Supply and License Agreements with New Wave
10th Feb 20207:00 amRNSNew BIO*AsterixT Product Line
28th Jan 20207:00 amRNSIntroduction of New Detergent Polymer
21st Jan 20202:14 pmRNSHolding(s) in Company
17th Jan 20207:00 amRNSTermination of Chelates Agreement
9th Jan 20207:00 amRNSFull Year Trading Update
8th Jan 20207:00 amRNSNew patent issued for detergent compositions
7th Jan 20207:00 amRNSFirst order to Croda for new odour control polymer
18th Dec 20198:00 amRNSCommencement of Trading on US OTCQB Market
24th Oct 20197:00 amRNSExpansion of Croda Supply & Joint Marketing Agrmt
23rd Oct 20197:00 amRNSIntroduction of New Odour Control Product Line
21st Oct 20195:57 pmRNSHolding(s) in Company
18th Oct 20197:00 amRNSTrading Update
27th Sep 20197:00 amRNSRecognition from Biofuels Digest
16th Sep 20195:11 pmRNSHolding(s) in Company
10th Sep 20197:00 amRNSInterim results
30th Aug 20193:17 pmRNSHolding(s) in Company
30th Aug 20197:00 amRNSAppointment of New Chief Financial Officer
22nd Aug 201911:05 amRNSSecond Price Monitoring Extn
22nd Aug 201911:00 amRNSPrice Monitoring Extension
20th Aug 20197:00 amRNSHolding(s) in Company
16th Aug 20199:00 amRNSPrice Monitoring Extension
6th Aug 20194:50 pmRNSHolding(s) in Company
5th Aug 20197:00 amRNSPDMR Shareholding
2nd Aug 20192:05 pmRNSSecond Price Monitoring Extn
2nd Aug 20192:00 pmRNSPrice Monitoring Extension
2nd Aug 201911:05 amRNSSecond Price Monitoring Extn
2nd Aug 201911:00 amRNSPrice Monitoring Extension
29th Jul 20196:03 pmRNSBlock listing Interim Review
19th Jul 20193:28 pmRNSResult of AGM
17th Jul 20197:00 amRNSHalf-Year Trading Update
10th Jul 20194:41 pmRNSSecond Price Monitoring Extn
10th Jul 20194:35 pmRNSPrice Monitoring Extension
9th Jul 20195:19 pmRNSHolding(s) in Company
27th Jun 20197:00 amRNSPreliminary Results
14th Jun 20197:00 amRNSNotice of Results
29th May 20197:00 amRNSSale of Minority Interest in Alkalon
21st May 20197:00 amRNSFirst personal care purchase order from Nouryon
20th May 20197:00 amRNSBoard Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.